Advertisement

Michael B. Atkins, MD, on Renal Cell Carcinoma: Phase II Findings on Nivolumab and Ipilimumab
0 seconds of 0 secondsVolume 90%
Press shift question mark to access a list of keyboard shortcuts
Keyboard Shortcuts
Play/PauseSPACE
Increase Volume
Decrease Volume
Seek Forward
Seek Backward
Captions On/Offc
Fullscreen/Exit Fullscreenf
Mute/Unmutem
Decrease Caption Size-
Increase Caption Size+ or =
Seek %0-9
00:00
00:00
00:00
 

Michael B. Atkins, MD, on Renal Cell Carcinoma: Phase II Findings on Nivolumab and Ipilimumab

2023 ASCO Genitourinary Cancers Symposium

Advertisement

Michael B. Atkins, MD, of Georgetown Lombardi Comprehensive Cancer Center, discusses treatment-free survival outcomes from the HCRN GU16-260-Cohort A study of patients with previously untreated advanced clear cell renal cell carcinoma who received nivolumab and salvage nivolumab plus ipilimumab. The regimen appears to result in substantial treatment-free survival with few treatment-related adverse events. (Abstract 604).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
This trial was a trial of nivo monotherapy followed by nivo/ipi boost for patients with treatment-naive clear cell metastatic kidney cancer. And we knew that immunotherapy can produce durable benefit even after treatment cessation, and also have some toxicities that occur after treatment cessation. And so we devised an endpoint called treatment-free survival that could characterize that period of time after treatment stops. And we've looked at this in patients with melanoma and kidney cancer on other trials, but those trials were flawed because the only reason why patients stopped was for toxicity or for disease progression, and there wasn't a built-in treatment endpoint. In the HCRN GU16-260 trial, there was a endpoint of treatment at 96 weeks, and so that gave us an opportunity to look at treatment-free survival in a situation where treatment stopped. And we looked at the data, now 37.7 months of follow-up and 128 patients were enrolled. And we looked at part A, which was nivo, and for the people who got nivo/ipi boost, part B, we looked at that as one regimen. And with that, and we looked at a 36 month period of time, and we defined treatment-free survival as the area between the registration and time to be getting a second therapy, and the time from registration and the time to stopping the first therapy. First of all, we saw that the response rate was 36%, 58% in the favorable risk population, and 27% in the intermediate and poor risk population, and that 68% of patients were alive at that three-year time point. And 38% of those patients who were alive were treatment free. But looking at that treatment-free survival on the graph, we saw that for the whole population, treatment-free survival was about 9.5 months. Overall survival average was 30 months, and 11.5 months on treatment and nine months on subsequent treatment. So treatment-free survival represented somewhere around a 36% of the total time. And in the favorable risk population, treatment-free survival was longer at 12.9 months. And in the intermediate poor risk population, it was shorter, around eight months and about 22% of that total time. But in each of those cases, it was longer than the treatment-free survival in the CheckMate 214 trial for the ipi/nivo arm showing the benefit of actually having a treatment cessation endpoint. So we concluded that treatment-free survival is an interesting endpoint for immunotherapy trials, gives information that is not captured with traditional endpoints, and having a trial with stopping therapy shows better the value of treatment-free survival. And it's something that should be potentially considered as a endpoint that patients care about for future trials. And then another thing, it continues to show in this trial how well the favorable risk population does with immune therapy, and argues for having a pure immune therapy in the favorable risk population.

Related Videos

Bladder Cancer

Andrea Necchi, MD, on Bladder Cancer: Phase II Results With Pembrolizumab Monotherapy

Andrea Necchi, MD, of Italy’s Vita-Salute San Raffaele University and the IRCCS San Raffaele Hospital and Scientific Institute, discusses new data from the KEYNOTE-057 trial on a novel systemic therapy for papillary high-risk non–muscle-invasive bladder cancer. The findings suggest that patients whose disease does not respond to bacillus Calmette-Guérin or who declined or were ineligible for a radical cystectomy may benefit from pembrolizumab monotherapy. (Abstract LBA442).

Kidney Cancer

Thomas Powles, MD, PhD, on Renal Cell Carcinoma: Phase III Results on Cabozantinib, Nivolumab, and Ipilimumab

Thomas Powles, MD, PhD, of Barts Health NHS Trust, Queen Mary University of London, discusses new data from the COSMIC-313 study of patients with advanced renal cell carcinoma of IMDC (International Metastatic RCC Database Consortium) intermediate or poor risk. Those who received cabozantinib instead of placebo with nivolumab and ipilimumab as first-line treatment seemed to experience improved progression-free survival. A subgroup analysis suggested the benefit was primarily in patients with an intermediate risk. Follow-up for overall survival is ongoing. (Abstract 605).

Bladder Cancer
Kidney Cancer
Prostate Cancer

Updates From City of Hope on Renal Cell, Prostate, and Urothelial Cancers

Sumanta K. Pal, MD, introduces his City of Hope colleagues, Hedyeh Ebrahimi, MD, MPH, who discusses the prevalence of dietary modification and supplement use in patients with metastatic renal cell carcinoma, and Daniela Castro, MSc, who discusses expanding eligibility criteria in kidney, prostate, and urothelial cancer trials to more accurately reflect the real-world population and reducing exclusion criteria. (Abstract 662, 612, 34, 453)

Bladder Cancer

Vadim S. Koshkin, MD, and Tanya Jindal, BS, BA, on Urothelial Carcinoma: Biomarkers of Response to Enfortumab Vedotin-ejfv

Vadim S. Koshkin, MD, and Tanya Jindal, BS, BA, both of the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discuss results from the retrospective UNITE study of biomarkers of response to the antibody-drug conjugate enfortumab vedotin-ejfv in patients with advanced urothelial carcinoma. Enfortumab vedotin is used widely in treatment-refractory disease, but there have been limited data available on biomarkers that may predict outcomes with this treatment. The UNITE study has now identified several potential biomarkers that need to be validated to help inform clinical decision-making and therapy sequencing. (Abstract 450).

Prostate Cancer

Daniel P. Petrylak, MD, on Prostate Cancer: Latest Data on Pembrolizumab Plus Docetaxel

Daniel P. Petrylak, MD, of the Yale Cancer Center, discusses phase III findings from the KEYNOTE-921 study, which was designed to assess the combination of pembrolizumab and docetaxel in the treatment of patients with metastatic castration-resistant prostate cancer. They had not received chemotherapy, but their disease progressed on the next-generation hormonal agent, or they could not tolerate the agent. (Abstract 19).

Advertisement

Advertisement




Advertisement